Synopsis :- The brokerage sees 43% upside driven by strong revenue growth, high client retention, margin expansion, AI-led enterprise positioning, improving unit economics, and attractive valuations compared to long-term earnings potential. A Recently listed company...
Synopsis: Fortis Healthcare is in focus after JP Morgan, Citi and UBS maintained bullish ratings, projecting up to 26% upside driven by strong Q3 operating performance, margin expansion and steady capacity additions. Robust hospital growth, improving diagnostics...
Synopsis: Siemens Energy India shares in focus after Jefferies initiated a ‘Buy’ on with a ₹3,700 target with an 35% upide potential, citing strong Q3 margins, YoY order book rise, and capacity expansion. As it Expects 40% EPS CAGR over FY25–28E underscores robust...
Synopsis: Infrastructure stock surged 7 percent on Q3 FY26 profit jump of 395 percent supported by strong non-aero revenues and brokerages projecting 33 percent upside. The share of this company, which is a leading global airport developer and operator, managing major...
Synopsis: M&M shares are in focus as top brokerages like Jefferies, Citi, and Morgan Stanley maintain Buy/Overweight ratings, citing robust UV and tractor performance, market-share gains, and strategic EV and PLI initiatives. The shares of one of the most...
Synopsis: G R Infraprojects Ltd gained attention after Axis Direct initiated a ‘Buy’ rating with a target of ₹1,540, implying 57% upside. Backed by a strong diversified order book and a healthy bidding pipeline, the company projects steady growth. The shares of...
Synopsis: Axis Direct has initiated a Buy with a ₹1,540 target, implying nearly 34% upside from ₹1,150. Margins improved to ₹8.3/scm despite higher Henry Hub prices, while volumes grew 7% YoY to 4.62 mmscmd. Management guides double-digit growth ahead with ₹1,200...
Synopsis: Max Financial gains after robust Q3 performance; Jefferies reiterates Buy with 23 percent upside, backed by strong premium growth, improved margins, and solid distribution momentum. The share of this company, which is primarily engaged in growing and...
Synopsis: Lenskart shares surged 13% after the company reported a sharp 6,550% YoY jump in Q3 FY26 PAT to Rs 133 crore, driven by 38% revenue growth. Strong operating leverage and margin expansion boosted profitability. Jefferies maintained a Buy rating, raising the...
Synopsis:- ICICI Direct maintains a Buy with ₹1,310 target, implying 38% upside. Q3 saw 16.7% YoY growth, led by 49% surge in sterile injectables. Radiopharma contributes 45% of the mix, with 81% exposure to the US. Vision 2030 targets doubling scale and achieving...
